Matinas BioPharma Successfully Reaches Agreement with FDA fo

20.02.2024 - ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will enroll approximately 216 patients ... Seite 1

Related Keywords

United States , American , Jeromed Jabbour , Theresa Matkovits , Compassionate Expanded Use Access Program , Drug Administration , Expanded Use Access Program , Chief Development Officer , Chief Executive Officer , Matinas Biopharma Holdings Chart , Atinas Biopharma Holdings Kurs , Atinas Biopharma Holdings Aktie ,